Blog
    Regulatory UpdateFor PhysiciansAugust 22, 2026

    FDA peptide regulatory status and GLP-1 safety signals

    Review FDA Category 2 bulk substance designations for BPC-157 and TB-500, plus emerging safety signals for Semaglutide including NAION and pulmonary aspiration.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    1. Clinical Question

    What is the current regulatory status of commonly compounded peptides under FDA sections 503A and 503B, and what safety signals have been identified in recent postmarketing surveillance and clinical trials?

    2. Evidence Snapshot

    • Regulatory Status: Multiple peptides (BPC-157, TB-500, CJC-1295, etc.) are currently designated as FDA Category 2 bulk substances as of March 2026.
    • Safety Signals (Semaglutide): Strong signals for nausea, vomiting, and delayed gastric emptying; emerging signals for NAION and pulmonary aspiration.
    • Clinical Trials (Weight Loss): Phase III results show 14.9% weight loss for Semaglutide (STEP 1) and 22.5% for Tirzepatide (SURMOUNT-1).
    • Clinical Trials (Other): Thymosin Alpha-1 showed no mortality reduction in Phase III sepsis trials (NCT02867267).

    3. What the Research Shows

    Regulatory Updates and Compliance

    As of March 2026, the FDA has classified several peptides as Category 2 bulk substances under Section 503A. This classification indicates significant safety risks or a lack of safety data, making these substances ineligible for routine compounding. Peptides in this category include BPC-157, TB-500, AOD-9604, and Semax.

    Specific regulatory actions include:

    • BPC-157: Designated Category 2 due to immunogenicity concerns and a lack of safety data. It has been the subject of warning letters to Tailor Made Compounding and Predator Nutrition.
    • Thymosin Alpha-1: While approved in over 35 countries as Zadaxin, it is not FDA-approved. Its 503A nomination was removed pending advisory review in September 2024, and it remains a substance of concern.
    • CJC-1295 and Ipamorelin: Both had nominations withdrawn or removed in September 2024. The FDA cited safety issues for CJC-1295, including increased heart rate.
    • GHK-Cu and GHRP-2: Both are listed under Category 2 for 503B compounding due to immunogenicity concerns.

    Safety Signals and Adverse Events

    Postmarketing data for Semaglutide (187,757 total GLP-1 reports through 2023) highlights several gastrointestinal and systemic concerns. Strong, label-identified signals include nausea, vomiting, and delayed gastric emptying. The latter has specific clinical relevance for pre-surgical patients due to concerns regarding pulmonary aspiration, a signal recently added to the Ozempic label in 2025.

    Emerging safety signals under evaluation include:

    • NAION (Nonarteritic Anterior Ischemic Optic Neuropathy): 96 cases reported through December 2024; currently under EMA review as of January 2025.
    • Intestinal Obstruction/Ileus: Added to postmarketing labels with instructions to monitor for symptoms.
    • Acute Kidney Injury: Detected primarily in the context of dehydration caused by gastrointestinal side effects.
    • Suicidal Ideation: Currently under FDA evaluation; data as of March 2026 do not support a higher risk compared to background rates.

    Clinical Trial Outcomes

    Phase III trials have established efficacy benchmarks for weight loss, with Semaglutide reaching 14.9% (PMID: 33567185) and Tirzepatide reaching 22.5% (PMID: 35658024). Retatrutide, a Phase II compound, showed 24.2% weight loss at 12mg. Conversely, Thymosin Alpha-1 failed to show mortality reduction in a Phase III sepsis trial. Tesamorelin demonstrated an 18% reduction in visceral adipose tissue (VAT) in pivotal Phase III trials for HIV lipodystrophy.

    4. Mechanism

    Mechanistic data provided focuses on the implications of safety signals:

    • Delayed Gastric Emptying: Contributes to pulmonary aspiration risk during general anesthesia and may impact the absorption of oral medications.
    • Immunogenicity: Cited by the FDA as a primary concern for BPC-157, TB-500, GHK-Cu, and GHRP-2, influencing their Category 2 status.
    • Tachycardia: Identified as a safety issue for CJC-1295 (increased heart rate).

    5. Limitations of the Evidence

    The primary limitation for many compounded peptides, including TB-500 and BPC-157, is a complete lack of human exposure and safety data. While peptides like Selank and Semax have approvals in Russia, they lack FDA approval or extensive clinical trial data in the United States. For emerging signals like NAION, the evidence is based on a limited number of cases (96) and is currently undergoing formal regulatory review, meaning a definitive causal link is not yet established in the provided data.

    6. Clinical Takeaway

    Physicians should note that BPC-157, TB-500, and several growth hormone secretagogues are currently restricted by the FDA under Category 2 due to safety and immunogenicity concerns. For approved GLP-1 RAs, clinical focus is shifting toward managing postmarketing signals such as delayed gastric emptying in surgical contexts and monitoring for emerging ophthalmic and obstructive gastrointestinal events.

    7. Sources

    • FDA Regulatory Status Records (March 2026)
    • FAERS Safety Signal Database (2023-2025)
    • Clinical Trial Records: NCT03548935, NCT04184622, NCT02867267, NCT00451282

    Referenced Peptides

    bpc 157semaglutidetirzepatidethymosin alpha 1cjc 1295

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.